Deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-19 and is reviewed periodically as new material appears.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
Temperature is a primary factor in peptide storage. Lower temperatures reduce molecular motion and slow degradation reactions, but freezing can concentrate solutes and promote aggregation. Lyophilized powders are commonly held at -20°C, whereas solutions are often kept at -80°C. Repeated freeze-thaw cycles are harmful because ice crystal formation and pH shifts can damage the peptide. The glass transition temperature of a lyophilized cake influences its stability; below this temperature, molecular mobility is restricted. For solutions, the choice between -20°C and -80°C depends on the peptide's sensitivity and the intended storage duration.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Temperature is the most common controlled variable, but its effect is not linear. Lower temperatures reduce most chemical reaction rates, yet freezing can concentrate solutes and create pH shifts in the remaining liquid phase. Repeated freeze-thaw cycles can denature or aggregate some peptides, especially those with hydrophobic segments. For lyophilized powders, desiccation and protection from moisture are often more important than deep freezing. For solutions, the choice between refrigeration and freezing depends on peptide concentration, buffer components, and the intended duration of storage.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear fluffy or crystalline |
| Solubility | Water-soluble, sequence-dependent | Some peptides require small amounts of organic solvent |
| Typical storage temperature | -20°C for lyophilized powder | -80°C for aqueous solutions; avoid frost-free freezers |
| Common analytical method | Reverse-phase HPLC | Used to assess purity and degradation products |
| Common synonyms | Peptide, polypeptide | Terminology varies with chain length and context |
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Peptides are short amino acid polymers whose stability depends on sequence, length, and chemical modifications. In dry form, most peptides are relatively stable because low water activity slows hydrolysis and other degradation. Residual moisture, oxygen, and light can still promote oxidation, deamidation, or aggregation over time. Storage recommendations therefore usually combine low temperature, desiccation, and protection from light. Because each peptide has distinct properties, no single condition fits every sequence.
Temperature selection balances degradation rate against physical changes. Many lyophilized peptides are stored at -20 °C, while some modified or longer sequences require -80 °C for extended periods. Aqueous stock solutions are less stable and are often kept at -20 °C or below in single-use aliquots. Repeated freeze-thaw cycles can cause aggregation, precipitation, or loss of activity, so aliquoting before freezing reduces that risk. Frost-free freezers cycle above freezing and may be unsuitable for long-term peptide storage.
Water is a central factor in peptide degradation because it enables hydrolysis and mobilizes reactive species. Lyophilized or dry powders typically remain stable for longer than solutions when kept cool and dry. Oxygen can drive oxidation, particularly for sulfur-containing residues, while light can catalyze side-chain damage. Buffer choice and pH influence charge state and can accelerate or slow deamidation and aggregation. Freeze-thaw cycles may concentrate solutes or promote ice-induced aggregation, so minimizing such cycles is a common handling goal.
Lyophilization removes water under vacuum from a frozen solution, leaving a porous cake or powder. Formulation excipients such as sugars or polyols can stabilize structure during freezing and drying and can raise the glass transition temperature. Residual moisture in the final product remains a critical variable because even small amounts can support hydrolysis over time. Storage recommendations often specify desiccation, darkness, and low temperature, though exact conditions depend on the peptide and its intended use. Stability studies measure changes under defined conditions rather than predicting absolute shelf life.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
This is one reason why extreme intakes of any one single micronutrient are not advised. Individuals with chronic digestive problems may be unable to absorb sufficient amounts of copper, even though the foods they eat are copper-rich. Several copper transporters have been identified that can move copper across cell membranes. Other intestinal copper transporters may exist. Intestinal copper uptake may be catalyzed by Ctr1. Ctr1 is expressed in all cell types so far investigated, including enterocytes, and it catalyzes the transport of Cu+1 across the cell membrane. Excess copper (as well as other heavy metal ions like zinc or cadmium) may be bound by metallothionein and sequestered within intracellular vesicles of enterocytes (i.e., predominant cells in the small intestinal mucosa).
Ember was an American company based in Boston, Massachusetts, USA, which is now owned by Silicon Labs. Ember had a radio development centre in Cambridge, England, and distributors worldwide. It developed Zigbee wireless networking technology that enabled companies involved in energy technologies to help make buildings and homes smarter, consume less energy, and operate more efficiently. The low-power wireless technology can be embedded into a wide variety of devices to be part of a self-organizing mesh network. All Ember products conform to IEEE 802.15.4-2003 standards. In May 2012, Ember was acquired by Silicon Labs.
=== Alternative names === The ghrelin cell is also known as an A-like cell (pancreas), X-cell (for unknown function), X/A-like cell (rats), Epsilon cell (pancreas), P/D sub 1 cell (humans) and Gr cell (abbreviation for ghrelin cell).
Sources: en.wikipedia.org
Genetically modified crops are genetically modified plants that are used in agriculture. The first crops developed were used for animal or human food and provide resistance to certain pests, diseases, environmental conditions, spoilage or chemical treatments (e.g. resistance to a herbicide). The second generation of crops aimed to improve the quality, often by altering the nutrient profile. Third generation genetically modified crops could be used for non-food purposes, including the production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.
==== Elimination ==== Psilocybin is eliminated 80% to 85% in urine and 15 to 20% in bile. It is excreted mainly in urine as psilocin-O-glucuronide. The drug was eliminated approximately 20% and 80% as psilocin O-glucuronide in different studies. The amount excreted as unchanged psilocin in urine is 1.5 to 3.4%. Studies conflict on the deaminated metabolites of psilocin, with one study finding that only 4% of psilocin is metabolized into 4-HIAA, 4-HIAL, and 4-HTOL and another that psilocybin is excreted 33% in urine as 4-HIAA. Findings also conflict on whether psilocybin can be detected in urine, with either no psilocybin excreted or 3% to 10% excreted as unchanged psilocybin. A majority of psilocybin and its metabolites is excreted within three hours with oral administration and elimination is almost complete within 24 hours. The elimination half-life of psilocybin, as psilocin, is 2.1 to 4.7 hours on average (range 1.2–18.6 hours) orally and 1.2 hours (range 1.8–4.5 hours) intravenously. Psilocin's elimination half-life in mice is 0.9 hours, much faster than in humans. Psilocin O-glucuronide's half-life is about 4 hours in humans and one hour in mice. No dose adjustment of psilocin is thought to be required as psilocin is inactivated mainly via metabolism as opposed to renal elimination. Accordingly, glomerular filtration rate (GFR) did not affect the pharmacokinetics of psilocybin.
== Production == Sucrose esters are mainly manufactured by using interesterification, the transfer of fatty acid from one ester to another. In this case, it means that the fatty acids used for the synthesis of sucrose esters are themselves in the esterified form. There are three processes that have been developed.
Sources: en.wikipedia.org
The pathophysiology of glaucoma is not well understood. Several theories exist regarding the mechanism of the damage to the optic nerve in glaucoma. The biomechanical theory hypothesizes that the retinal ganglion-cell axons (which form the optic nerve head and the retinal nerve fiber layer) are particularly susceptible to mechanical damage from increases in the intraocular pressure as they pass through pores at the lamina cribrosa. Thus, increases in intraocular pressure would cause nerve damage as seen in glaucoma. The vascular theory hypothesizes that a decreased blood supply to the retinal ganglion cells leads to nerve damage. This decrease in blood supply may be due to increasing intraocular pressures, and may also be due to systemic hypotension, vasospasm, or atherosclerosis. This is supported by evidence that those with low blood pressure, particularly low diastolic blood pressure, are at an increased risk of glaucoma. The primary neurodegeneration theory hypothesizes that a primary neurodegenerative process may be responsible for degeneration at the optic nerve head in glaucoma. This would be consistent with a possible mechanism of normal tension glaucoma (those with open-angle glaucoma with normal eye pressures) and is supported by evidence showing a correlation of glaucoma with Alzheimer's dementia and other causes of cognitive decline. Both experimental and clinical studies implicate that oxidative stress plays a role in the pathogenesis of open-angle glaucoma as well as in Alzheimer's disease.
==== Comparison of pharmacokinetics between dosage forms ==== The free acid (HMB-FA) and monohydrated calcium salt (HMB-Ca) forms of HMB have different pharmacokinetics. HMB-FA is more readily absorbed into the bloodstream and has a longer elimination half-life (3 hours) relative to HMB-Ca (2.5 hours). Tissue uptake and utilization of HMB-FA is 25–40% higher than for HMB-Ca. The fraction of an ingested dose that is excreted in urine does not differ between the two forms.
== Side effects == Neumega has caused allergic reaction which at times have been very serious. Symptoms have been edema of the face and tongue, or larynx; shortness of breath; wheezing; chest pain; hypotension (including shock); dysarthria; loss of consciousness, rash, urticaria, flushing, and fever. These reaction can occur after the first dose or after any later application. Neumega should be permanently discontinued in patients with any sign of allergy. Treatment is largely symptomatic. Oprelvekin also has caused quite often fluid retention, ranging from peripheral edema (approximately 40% of patients) to dyspnea and full developed lung edema with or without cardiac decompensation (see contraindications and precautions). These symptoms have led to some deaths. Fluid retention may also lead to dilutional anemia (in 10 to 15% of patients). Hypokalemia may also result. Symptoms of fluid retention have been observed more often in patients following myeloablative chemotherapy (see contraindications). Severe arrhythmias (atrial flutter and atrial fibrillation) as well as fatal cardiac arrest have also been seen which may or may be not attributed to fluid retention/increased volume. Isolated cases of stroke have been noted, those patients with previous transient ischemic attacks or partial/minor strokes may be at particular risk. Papilledema of the eyes has been observed (2%) and may lead to disturbed visual acuity and even temporary or permanent blindness. Patients with preexisting papilledema or with involvement of the central nervous system may be at higher risk.
Sources: en.wikipedia.org
Removing water reduces hydrolytic degradation and limits microbial growth. Lyophilized powders are generally more stable at higher temperatures than aqueous solutions. They also tolerate shipping with less risk of degradation.
pH determines the charge state of ionizable groups, which affects solubility and conformational stability. Extremes of pH can accelerate deamidation, hydrolysis, or aggregation. The optimal pH range is peptide-specific and is often identified during formulation development.
Repeated freezing and thawing can cause aggregation, precipitation, or loss of activity. Ice crystal formation and transient pH changes are among the mechanisms. Preparing single-use portions avoids repeated cycling.
Lyophilized peptides have low water activity, which slows hydrolysis and many oxidative pathways. Low temperatures further reduce residual chemical reactivity and microbial growth risk. The exact temperature depends on peptide stability data and expected storage duration.